Shares in ChronTech Pharma AB plunged as much as 40 percent during trading Tuesday on news that ChronVac-C, the company's therapeutic DNA vaccine for treating hepatitis C virus (HCV) infection, failed to attain efficacy in an interim analysis of data from a Phase II trial.
Read More
A fault in glucose metabolism lies at the heart of polycystic kidney disease, a common inherited condition that can cause end-stage renal failure by the age of 50, new research has shown.
Read More
Themis Bioscience GmbH is planning to begin clinical trials of viral vaccine candidates to protect against dengue virus and chikungunya virus infections before year-end, following successful preclinical proof of concept studies.
Read More
Following the FDA approvals of the first two antibody-drug conjugates (ADCs), the market is moving forward to develop enhanced products based on linker technologies that will make that new class of biopharmaceutical/small-molecule hybrids safer, more effective and easier to manufacture.
Read More
ReNeuron plc is planning to move its stem cell therapy ReN001 into a Phase I trial in critical limb ischemia (CLI), just as Aastrom Biosciences Inc., an erstwhile leader in the field, is stepping away from the fray.
Read More
• InteRNA Technologies BV, of Bilthoven, the Netherlands, closed an equity financing round, with participation from new investors Innovation and Investment Fund Gelderland and several angel investors.
Read More
